VIDEO: Axitinib shows clinically meaningful treatment burden reduction in wet AMD

ByDavid A. Eichenbaum, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.

The axitinib intravitreal implant (Ocular Therapeutix) demonstrated a clinically meaningful treatment reduction compared with aflibercept, according to Eichenbaum. The implant also yielded stable visual acuity and anatomy.

“The pharmacodynamics that we see with axitinib support a treatment that would probably be able to be dosed every 9 to 12 months,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Eichenbaum DA. Fifty-two-week sustained efficacy and treatment burden reduction with OTX-TKI in the U.S. phase 1 trial for nAMD. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Disclosures: Eichenbaum reports being a consultant and investigator for Ocular Therapeutix.

American Academy of Ophthalmology Meeting

Read more

VIDEO: Axitinib shows clinically meaningful treatment burden reduction in wet AMD

Related Content